Update on the Treatment of Glucocorticoid-Induced Osteoporosis
Osteoporosis and osteoporotic fracture are one of the most common side effects of glucocorticoid therapy. All patients who are taking any dose of glucocorticoids for over 3 months should have a bone health assessment. After consideration of their clinical risk factors, glucocorticoid dose, bone mine...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
World Scientific Publishing
2022-06-01
|
| Series: | Journal of Clinical Rheumatology and Immunology |
| Subjects: | |
| Online Access: | https://www.worldscientific.com/doi/10.1142/S2661341722300038 |
| _version_ | 1811241775640084480 |
|---|---|
| author | Ai Lee Lim Swan Sim Yeap |
| author_facet | Ai Lee Lim Swan Sim Yeap |
| author_sort | Ai Lee Lim |
| collection | DOAJ |
| description | Osteoporosis and osteoporotic fracture are one of the most common side effects of glucocorticoid therapy. All patients who are taking any dose of glucocorticoids for over 3 months should have a bone health assessment. After consideration of their clinical risk factors, glucocorticoid dose, bone mineral density measurement, and the Fracture Risk Assessment Tool score, patients can be stratified into low-, moderate-, and high-risk groups. General measures include optimization of calcium and vitamin D intake, reducing glucocorticoid dosage and lifestyle modifications. In patients with moderate to high risk of fracture, pharmacological agents should be prescribed, of which bisphosphonates, denosumab, and teriparatide are the most widely used. |
| first_indexed | 2024-04-12T13:41:13Z |
| format | Article |
| id | doaj.art-8f8a15120fd145478ebefe625dbde92d |
| institution | Directory Open Access Journal |
| issn | 2661-3417 2661-3425 |
| language | English |
| last_indexed | 2024-04-12T13:41:13Z |
| publishDate | 2022-06-01 |
| publisher | World Scientific Publishing |
| record_format | Article |
| series | Journal of Clinical Rheumatology and Immunology |
| spelling | doaj.art-8f8a15120fd145478ebefe625dbde92d2022-12-22T03:30:51ZengWorld Scientific PublishingJournal of Clinical Rheumatology and Immunology2661-34172661-34252022-06-0122Supp01485510.1142/S2661341722300038Update on the Treatment of Glucocorticoid-Induced OsteoporosisAi Lee Lim0Swan Sim Yeap1Rheumatology Unit, Hospital Pulau Pinang, Penang, MalaysiaDepartment of Medicine, Subang Jaya Medical Centre, Selangor, MalaysiaOsteoporosis and osteoporotic fracture are one of the most common side effects of glucocorticoid therapy. All patients who are taking any dose of glucocorticoids for over 3 months should have a bone health assessment. After consideration of their clinical risk factors, glucocorticoid dose, bone mineral density measurement, and the Fracture Risk Assessment Tool score, patients can be stratified into low-, moderate-, and high-risk groups. General measures include optimization of calcium and vitamin D intake, reducing glucocorticoid dosage and lifestyle modifications. In patients with moderate to high risk of fracture, pharmacological agents should be prescribed, of which bisphosphonates, denosumab, and teriparatide are the most widely used.https://www.worldscientific.com/doi/10.1142/S2661341722300038GlucocorticoidOsteoporosisAssessmentDiagnosisTreatmentManagement |
| spellingShingle | Ai Lee Lim Swan Sim Yeap Update on the Treatment of Glucocorticoid-Induced Osteoporosis Journal of Clinical Rheumatology and Immunology Glucocorticoid Osteoporosis Assessment Diagnosis Treatment Management |
| title | Update on the Treatment of Glucocorticoid-Induced Osteoporosis |
| title_full | Update on the Treatment of Glucocorticoid-Induced Osteoporosis |
| title_fullStr | Update on the Treatment of Glucocorticoid-Induced Osteoporosis |
| title_full_unstemmed | Update on the Treatment of Glucocorticoid-Induced Osteoporosis |
| title_short | Update on the Treatment of Glucocorticoid-Induced Osteoporosis |
| title_sort | update on the treatment of glucocorticoid induced osteoporosis |
| topic | Glucocorticoid Osteoporosis Assessment Diagnosis Treatment Management |
| url | https://www.worldscientific.com/doi/10.1142/S2661341722300038 |
| work_keys_str_mv | AT aileelim updateonthetreatmentofglucocorticoidinducedosteoporosis AT swansimyeap updateonthetreatmentofglucocorticoidinducedosteoporosis |